2 results match your criteria: "Central Hospital in Xinxiang City[Affiliation]"
[Infection Status and Prognosis Analysis of Epstein-Barr Virus in Patients with Newly Diagnosed Hodgkin's Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
October 2016
Department of Hmatology, Central Hospital in Xinxiang City, Xinxiang 453000, Henan Province, China. E-mail:
Objective: To investigate the Epstein Barr virus(EBV) positive rate in newly diagnosed Hodgkin's lymphoma(HL) and the prognostic significance of EBV status.
Methods: A total of 120 previously untreated patients with histologically confirmed Hodgkin's lymphoma were enrolled in this study. The EBV infection status was confirmed through examining EBV-RNA(EBER) or EBV latent membrane protein-1, and these patients were divided into EBV positive group and EBV negative group.
[Clinical Comparative Study of Two Kind Doses of Bortezomib Combinated with Bisphosphonates for Treating Patients with Multiple Myeloma Ostespathy].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
June 2016
Department of Hematology, Central Hospital in Xinxiang City, Xinxiang 453000, Henan Province, China.
Objective: To investigate the clinical efficacy and safety of conventional dose and reduction dose of bortezomib in combination with bisphosphonates for treating patients with multiple myeloma ostespathy.
Methods: A total of 150 patients with multiple myeloma ostespathy were chosen in the period from March 2011 to July 2015 and randomly were divided into 2 groups: A group (75 cases) and B group (75 cases). The patients in A and B groups were treated with conventional dose of bortezomib and reduction dose of bortezomib on the basis of bisphosphonates respectively and the clinical efficacy, the improvement rate of life quality, NRS score, levels of IL-6 and CRP before and after treatment, and the adverse effects of 2 groups were compared.